Specifying the Anti-inflammatory Effects of Ziltivekimab

Summary

The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.

Timeline

Start

2024-05-03

Primary completion

2026-07-01

Completion

2026-10-01

Drugs

Indications